27508512|t|A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays
27508512|a|Immunogenicity to therapeutic proteins has been linked to loss of response by a large percentage of patients taking anti-tumor necrosis factor-alpha agents. Drug monitoring can be extremely useful, allowing physicians to adjust the therapeutic scheme individually. This article aims to systematically review the published data with respect to cutoff levels of infliximab (IFX) and adalimumab (ADA) and relate them to the methodology adopted for quantification of IFX and ADA levels and clinical outcomes. The PubMed database was searched to identify studies focusing on the association between IFX or ADA cutoff levels and clinical outcomes in patients with inflammatory bowel disease. Of the 1654 articles initially selected by queries, 20 were included. A receiver operating characteristic curve analysis was performed to identify cutoff levels of IFX or ADA that correlated with a clinical outcome, but only 6 studies performed the same analysis for antidrug antibody levels. Cutoff levels were different between studies. The methodology chosen for level quantifications, clinical outcomes, and sample size and characteristics were also different. Nevertheless, measurement of drug levels should be performed during maintenance, and with loss of response, with persistent high levels of C-reactive protein, and when mucosal lesions are still present. In these scenarios, drug and antidrug levels were correlated with clinical outcomes. Concerning drug levels monitoring any methodology is adequate. With respect to antidrug antibody levels, it will be necessary to define a gold standard method or to establish different cutoff levels for different methodologies.
27508512	2	19	Systematic Review	T170	C1955832
27508512	23	33	Infliximab	T116,T121,T129	C0666743
27508512	38	48	Adalimumab	T116,T121,T129	C1122087
27508512	49	64	Drug Monitoring	T058	C0085421
27508512	66	72	Levels	T080	C0441889
27508512	74	91	Clinical Outcomes	T033	C2985631
27508512	96	102	Assays	T059	C1510438
27508512	103	117	Immunogenicity	T062	C4054739
27508512	121	141	therapeutic proteins	T121	C0872285
27508512	161	165	loss	T081	C1517945
27508512	169	177	response	T032	C0871261
27508512	183	188	large	T081	C0549177
27508512	189	199	percentage	T078	C1549488
27508512	203	211	patients	T101	C0030705
27508512	219	258	anti-tumor necrosis factor-alpha agents	T121	C1562242
27508512	260	275	Drug monitoring	T058	C0085421
27508512	283	292	extremely	T080	C0205403
27508512	293	299	useful	T080	C3827682
27508512	310	320	physicians	T097	C0031831
27508512	324	330	adjust	T169	C0456081
27508512	335	346	therapeutic	T169	C0302350
27508512	347	353	scheme	T170	C1519193
27508512	354	366	individually	T098	C0237401
27508512	373	380	article	T170	C1706852
27508512	381	385	aims	T078	C1947946
27508512	389	410	systematically review	T170	C1955832
27508512	415	429	published data	T170	C0993637
27508512	435	442	respect	T080	C0205345
27508512	446	459	cutoff levels	T169	C1442160
27508512	463	473	infliximab	T116,T121,T129	C0666743
27508512	475	478	IFX	T116,T121,T129	C0666743
27508512	484	494	adalimumab	T116,T121,T129	C1122087
27508512	496	499	ADA	T116,T121,T129	C1122087
27508512	524	535	methodology	T078	C3266812
27508512	536	543	adopted	T080	C1272684
27508512	548	562	quantification	T081	C1709793
27508512	566	569	IFX	T116,T121,T129	C0666743
27508512	574	577	ADA	T116,T121,T129	C1122087
27508512	578	584	levels	T080	C0441889
27508512	589	606	clinical outcomes	T033	C2985631
27508512	612	627	PubMed database	T170	C1138432
27508512	632	640	searched	T052	C1706202
27508512	644	652	identify	T041	C0020792
27508512	653	660	studies	T062	C2603343
27508512	661	669	focusing	T169	C1285542
27508512	677	688	association	T080	C0439849
27508512	689	696	between	T082	C0205103
27508512	697	700	IFX	T116,T121,T129	C0666743
27508512	704	707	ADA	T116,T121,T129	C1122087
27508512	708	721	cutoff levels	T169	C1442160
27508512	726	743	clinical outcomes	T033	C2985631
27508512	747	755	patients	T101	C0030705
27508512	761	787	inflammatory bowel disease	T047	C0021390
27508512	801	809	articles	T170	C1706852
27508512	810	819	initially	T079	C0205265
27508512	820	828	selected	T052	C1707391
27508512	832	839	queries	T170	C1522634
27508512	849	857	included	T169	C0332257
27508512	861	900	receiver operating characteristic curve	T081	C0035787
27508512	901	909	analysis	T062	C0936012
27508512	914	923	performed	T169	C0884358
27508512	927	935	identify	T041	C0020792
27508512	936	949	cutoff levels	T169	C1442160
27508512	953	956	IFX	T116,T121,T129	C0666743
27508512	960	963	ADA	T116,T121,T129	C1122087
27508512	969	979	correlated	T080	C1707520
27508512	987	1003	clinical outcome	T033	C2985631
27508512	1016	1023	studies	T062	C2603343
27508512	1024	1033	performed	T169	C0884358
27508512	1038	1042	same	T080	C0445247
27508512	1043	1051	analysis	T062	C0936012
27508512	1056	1073	antidrug antibody	T116,T129	C3811629
27508512	1074	1080	levels	T080	C0441889
27508512	1082	1095	Cutoff levels	T169	C1442160
27508512	1101	1110	different	T080	C1705242
27508512	1111	1118	between	T082	C0205103
27508512	1119	1126	studies	T062	C2603343
27508512	1132	1143	methodology	T078	C3266812
27508512	1144	1150	chosen	T052	C1707391
27508512	1155	1160	level	T080	C0441889
27508512	1161	1176	quantifications	T081	C1709793
27508512	1178	1195	clinical outcomes	T033	C2985631
27508512	1201	1212	sample size	T081	C0242618
27508512	1217	1232	characteristics	T080	C1521970
27508512	1243	1252	different	T080	C1705242
27508512	1268	1294	measurement of drug levels	T059	C1261153
27508512	1305	1314	performed	T169	C0884358
27508512	1322	1333	maintenance	T052	C0024501
27508512	1344	1348	loss	T081	C1517945
27508512	1352	1360	response	T032	C0871261
27508512	1367	1377	persistent	T079	C0205322
27508512	1383	1389	levels	T080	C0441889
27508512	1393	1411	C-reactive protein	T116,T129	C0006560
27508512	1422	1429	mucosal	T024	C0026724
27508512	1430	1437	lesions	T033	C0221198
27508512	1448	1455	present	T033	C0150312
27508512	1466	1475	scenarios	T169	C0683579
27508512	1477	1481	drug	T121	C0013227
27508512	1486	1494	antidrug	T123	C0005515
27508512	1495	1501	levels	T080	C0441889
27508512	1507	1517	correlated	T080	C1707520
27508512	1523	1540	clinical outcomes	T033	C2985631
27508512	1553	1557	drug	T121	C0013227
27508512	1558	1564	levels	T080	C0441889
27508512	1565	1575	monitoring	T058	C1283169
27508512	1580	1591	methodology	T078	C3266812
27508512	1595	1603	adequate	T080	C0205411
27508512	1610	1620	respect to	T080	C0205345
27508512	1621	1638	antidrug antibody	T116,T129	C3811629
27508512	1639	1645	levels	T080	C0441889
27508512	1658	1667	necessary	T080	C3898777
27508512	1680	1693	gold standard	T080	C0150110
27508512	1694	1700	method	T170	C0025663
27508512	1707	1716	establish	T080	C0443211
27508512	1717	1726	different	T080	C1705242
27508512	1727	1740	cutoff levels	T169	C1442160
27508512	1745	1754	different	T080	C1705242
27508512	1755	1768	methodologies	T078	C3266812